PMID- 9371344
OWN - NLM
STAT- MEDLINE
DCOM- 19980123
LR  - 20220321
IS  - 0066-4804 (Print)
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Linking)
VI  - 41
IP  - 11
DP  - 1997 Nov
TI  - Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.
PG  - 2424-7
AB  - The objective of this study was to analyze the pharmacokinetics of cefepime, in 
      six patients with acute renal failure related to septic shock, during continuous 
      venovenous hemodiafiltration (CVVHD) (Hemospal AN 69S hemofilter; Hospal, Lyon, 
      France). Six patients, mean age 65 +/- 4 years (range, 61 to 69), were included 
      and each received 2 g of cefepime by intravenous infusion over a 30-min period 
      every 12 h. Prefilter serum, dialysate outlet (DO), and ultrafiltrate samples 
      were collected 0.47, 0.50, 0.57, 1, 3, 5, 7, and 12 h after the beginning of 
      infusion. The time design of samples was optimized in accordance with the theory 
      of D optimality. The cefepime concentrations were measured by high-performance 
      liquid chromatography. The pharmacokinetics computation was carried out using 
      P-PHARM software. Mean serum concentration peaks were 53 +/- 21.9 mg/liter 
      (range, 13.0 to 68.9) one-half hour after the infusion. The mean elimination 
      half-life was 8.11 +/- 2.22 h (range, 4.76 to 10.84). DO clearance was 66.57 +/- 
      30.14 ml/min (range, 38.66 to 119.87). The mean volume of distribution was 0.71 
      +/- 0.37 liters/kg of body weight. CVVHD was effective for cefepime elimination. 
      In these subjects, the elimination half-life and DO clearance were almost 
      constant. The results of this study suggested that a 2-g twice-daily infusion 
      (usual dosage) was required for an effective concentration in this group of 
      patients.
FAU - Allaouchiche, B
AU  - Allaouchiche B
AD  - Department of Intensive Care, Edouard Herriot Hospital, Lyon, France. 
      allaouch@univ-lyon1.fr
FAU - Breilh, D
AU  - Breilh D
FAU - Jaumain, H
AU  - Jaumain H
FAU - Gaillard, B
AU  - Gaillard B
FAU - Renard, S
AU  - Renard S
FAU - Saux, M C
AU  - Saux MC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Cephalosporins)
RN  - 807PW4VQE3 (Cefepime)
SB  - IM
MH  - Acute Kidney Injury/*metabolism
MH  - Aged
MH  - Cefepime
MH  - Cephalosporins/administration & dosage/blood/*pharmacokinetics
MH  - Female
MH  - Half-Life
MH  - *Hemofiltration
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
PMC - PMC164139
EDAT- 1997/11/26 00:00
MHDA- 1997/11/26 00:01
PMCR- 1997/11/01
CRDT- 1997/11/26 00:00
PHST- 1997/11/26 00:00 [pubmed]
PHST- 1997/11/26 00:01 [medline]
PHST- 1997/11/26 00:00 [entrez]
PHST- 1997/11/01 00:00 [pmc-release]
AID - 10.1128/AAC.41.11.2424 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 1997 Nov;41(11):2424-7. doi: 10.1128/AAC.41.11.2424.